Tenon Medical Inc.
TNON evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TNON—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TNON
Tenon Medical Inc. (TNON) is a commercial-stage medical device company focused on the sacroiliac joint fusion market, currently operating with limited cash reserves and an accumulated deficit, while pursuing commercial expansion and additional financing.
Key risk: Cash runway insufficient
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tenon Medical Inc. (TNON) is a commercial-stage medical device company focused on the sacroiliac joint fusion market, currently operating with limited cash reserves and an accumulated deficit, while pursuing commercial expansion and additional financing.
- Cash and cash equivalents of $1.7M as of 2026-06-30 [sec].
- Total revenue of $1.3M for the six months ended 2026-06-30 [sec].
- Net loss of $4.0M for the six months ended 2026-06-30 [sec].
- Accumulated deficit of $84.8M as of 2026-03-31 [sec_mda · as of 2026-05-15].
- Existing cash not sufficient to fund operations for the next 12 months; company plans to raise additional capital [sec_mda · as of 2026-08-13].
What works
- Revenue generation of $1.3M in the first half of 2026 indicates commercial traction [sec].
- Company is actively pursuing commercial expansion, including hiring direct sales reps and expanding distribution network [sec · filed 2026-08-11].
- Plans to continue clinical research studies to support reimbursement and coverage efforts [sec · filed 2026-08-11].
What to weigh
- Cash and cash equivalents of $1.7M as of 2026-06-30 are insufficient to fund operations for the next 12 months [sec_mda · as of 2026-08-13].
- Accumulated deficit of $84.8M as of 2026-03-31 and ongoing net losses indicate a history of unprofitability [sec_mda · as of 2026-05-15].
- Company has not achieved positive cash flow from operations to date [sec_mda · as of 2026-05-15].
- Dependence on future capital raises through equity or debt offerings introduces dilution and financing risk [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Cash and cash equivalents as of June 30, 2026
“As of June 30, 2026, we had cash and cash equivalent”
SEC MD&A · August 13, 2026
Accumulated deficit as of March 31, 2026
“As of March 31, 2026, we had an accumulated deficit of $84.8 million”
SEC MD&A · May 15, 2026
Cash not sufficient for 12 months
“our existing cash and cash equivalents will not be sufficient to fund our operating expenses and working capital requirements through at least the next 12 months”
SEC MD&A · May 15, 2026
Plans to raise additional capital
“We plan to raise the necessary additional capital through one or a combination of public or private equity offerings, debt financings, and collaborations.”
SEC MD&A · August 13, 2026
Risks & what to watch (4)›
Key risks
- Cash runway insufficient — Cash of $1.7M as of 2026-06-30 is not enough to fund operations for the next 12 months [sec_mda · as of 2026-08-13].
- History of losses — Accumulated deficit of $84.8M as of 2026-03-31 and no positive cash flow from operations to date [sec_mda · as of 2026-05-15].
- Dependence on future financing — Company must raise additional capital through equity or debt, which may be dilutive or unavailable [sec_mda · as of 2026-08-13].
- Regulatory and market risks — Forward-looking statements note risks from FDA regulatory changes and ability to maintain clearances [sec · filed 2026-06-22].
What to watch
- Ability to raise additional capital through equity or debt offerings [sec_mda · as of 2026-08-13].
- Progress in commercial expansion, including hiring and distribution network growth [sec · filed 2026-08-11].
- Revenue growth trajectory and path to positive cash flow [sec].
- Results from clinical studies supporting reimbursement and coverage [sec · filed 2026-08-11].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Tenon Medical Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Tenon Medical Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
2.8 months
OCF -$3M · Net income -$4M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
8
Total value held
$278K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 167,486 | $122K |
| vanguard capital management llc | 143,430 | $104K |
| vanguard fiduciary trust co | 44,628 | $32K |
| northern trust corp | 18,048 | $13K |
| citigroup inc | 9,857 | $7K |
| morgan stanley | 188 | $136 |
| bnp paribas financial markets | 24 | $17 |
| allworth financial lp | 20 | $15 |
Short Interest
as of May 22, 2026- % of float
- 1.9%
- Days to cover
- 2.3
- Shares short
- 193,192
- Daily short volume (Jun 18, 2026)
- 71.5%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TNON short interestGovernance
Frequently asked questions
What is the AI investment thesis for Tenon Medical Inc.?
Tenon Medical Inc. (TNON) is a commercial-stage medical device company focused on the sacroiliac joint fusion market, currently operating with limited cash reserves and an accumulated deficit, while pursuing commercial expansion and additional financing.
Who is the CEO of Tenon Medical Inc.?
Mr. Steven M. Foster is the chief executive officer of Tenon Medical Inc. (TNON).
Where is Tenon Medical Inc. headquartered?
Tenon Medical Inc. (TNON) is headquartered in Los Gatos, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.